CSPIA
ROIV icon

Cary Street Partners Investment Advisory’s Roivant Sciences ROIV Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-954
Closed -$26.4K – 779
2026
Q1 		$26.4K Buy
+954
New +$24.5K 0.01% 598

Other funds holding ROIV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Cary Street Partners Investment Advisory's ROIV Position: Q2 2026 in Review

Cary Street Partners Investment Advisory sold out of Roivant Sciences (ROIV) in Q2 2026, closing a stake of 954 shares — an estimated $26.4K sold.

Cary Street Partners Investment Advisory first reported a position in ROIV in Q1 2026 and held it in 1 quarter. The position peaked at $26.4K in Q1 2026. 266 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Cary Street Partners Investment Advisory reported no remaining Roivant Sciences position as of Q2 2026 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 954 Roivant Sciences shares in Q2 2026, an estimated $26.4K.
  • Cary Street Partners Investment Advisory first reported a position in Roivant Sciences in Q1 2026 and held it in 1 quarter.
  • Cary Street Partners Investment Advisory's Roivant Sciences position peaked at $26.4K in Q1 2026.
  • 266 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Cary Street Partners Investment Advisory's 13F filing for Q2 2026, filed 17 Jul 2026.